NCT00242723 2026-04-17
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
National Institutes of Health Clinical Center (CC)
Recruiting
Clinical Trials
48 trialsNCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT07443020 2026-04-07
RIOT 4B
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT07510815 2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT07277413 2026-04-03
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Phase 1 Recruiting
NCT06097728 2026-04-02
eVOLVE-Meso
AstraZeneca
Phase 3 Recruiting
NCT06251310 2026-04-01
SW-682 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1 Recruiting
NCT05655078 2026-03-30
HIT-Meso
University College, London
Phase NA Recruiting
NCT06840834 2026-03-16
Bi-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
NCT06051695 2026-02-20
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT06566079 2026-02-17
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Recruiting
NCT07126509 2026-02-17
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
University of Chicago
Phase NA Recruiting
NCT07403630 2026-02-17
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
Phase NA Recruiting
NCT04981119 2026-02-13
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
NCT05568680 2026-02-10
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
Phase 1 Recruiting
NCT07192900 2026-01-15
(RIOT 4A)
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT03760575 2025-12-04
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT03007030 2025-11-10
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04400539 2025-09-25
IMPALA
University Hospital, Lille
Phase 2 Recruiting
NCT06037941 2025-09-22
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT06581549 2025-09-05
Imaging-Meso
Istituto Oncologico Veneto IRCCS
Recruiting
NCT05538806 2025-08-22
TIGER Meso
NovoCure Ltd.
Recruiting
NCT07121374 2025-08-13
NECIM
University Hospital, Antwerp
Phase 1/2 Recruiting
NCT06756035 2025-07-31
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
Phase 1 Recruiting
NCT06057935 2025-07-22
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06477419 2025-07-15
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06790082 2025-07-03
FAPI-PM
Aalborg University Hospital
Phase 2 Recruiting
NCT03917043 2025-06-18
APG-2449 in Patients With Advanced Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT05944237 2025-06-08
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Phase 1/2 Recruiting
NCT05188859 2025-05-31
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06318286 2025-05-25
PENINSULA
Hyogo Medical University
Phase 2 Recruiting
NCT04104776 2025-05-15
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
Phase 1/2 Recruiting
NCT04515836 2025-05-06
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
Phase 2 Recruiting
NCT06946498 2025-04-27
FLAT
National and Kapodistrian University of Athens
Phase NA Recruiting
NCT05304208 2025-04-25
ENSURE
Erasmus Medical Center
Phase 1 Recruiting
NCT06910449 2025-04-08
Hemithoracic Arc Radiotherapy Post Pleural Decortication
Cairo University
Phase NA Recruiting
NCT05628376 2025-04-02
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
University College, London
Recruiting
NCT06886672 2025-03-20
MAGNETS
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT04996017 2025-03-13
AtezoMeso
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3 Recruiting
NCT06726564 2024-12-10
A Study of MT027 in Patients with Pleural Malignant Tumors
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1 Recruiting
NCT06637345 2024-10-15
MESORTIBO
Centro di Riferimento Oncologico - Aviano
Recruiting
NCT06451536 2024-06-11
FAPBI
Ankara University
Phase NA Recruiting
NCT05765084 2024-05-16
Immuno-MESODEC
University Hospital, Antwerp
Phase 1/2 Recruiting
NCT06410625 2024-05-16
FLT-MM
Ankara University
Phase NA Recruiting
NCT05930665 2024-02-21
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Sun Yat-sen University
Phase 2 Recruiting
NCT06031636 2023-09-11
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
Tianjin Medical University Second Hospital
Recruiting